Physician profile
Ray Rodriguez
NPI 1154324366
$28,402.01
in general payments reported to CMS, 2019-2025
16 companies · $495 in 2025
The $495 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $21K · 2020: $4,624 · 2021: $1,779 · 2022: $90.08 · 2023: $174 · 2024: $635 · 2025: $495.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,205 · Education: $99.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,205.00 |
| Education | $99.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $20,466.05 | 2019 | |
| Biocryst Pharmaceuticals, INC. | $2,750.00 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $2,137.50 | 2020-2021 | |
| Biocryst US Sales Co., LLC | $1,524.68 | 2021-2023 | Orladeyo |
| Astrazeneca Pharmaceuticals Lp | $515.15 | 2020-2025 | Tezspire, Fasenra |
| Regeneron Healthcare Solutions, INC. | $262.57 | 2024-2025 | Dupixent |
| Biomarin Pharmaceutical INC. | $229.29 | 2024 | |
| Glaxosmithkline, LLC. | $220.37 | 2019-2024 | Arexvy |
| Genzyme Corporation | $192.63 | 2021-2025 | |
| Amgen INC. | $51.47 | 2024 | Tezspire |
| Jubilant Hollisterstier LLC | $24.89 | 2025 | |
| Astellas Pharma US INC | $14.90 | 2019 | |
| Incyte Corporation | $12.51 | 2022 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ray Rodriguez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.